cognitive impairment

Alto Neuroscience’s ALTO-101, a novel PDE4 inhibitor, received FDA Fast Track designation for treating cognitive impairment associated with schizophrenia (CIAS), a condition with no approved treatments. Phase 1 data showed ALTO-101 improved EEG measures and cognitive performance in healthy volunteers. A Phase 2 proof-of-concept study in CIAS patients is ongoing. The Fast Track designation allows for more frequent FDA communication and potential accelerated approval. Alto uses a Precision Psychiatry Platform to identify patients most likely to respond to their therapies.

Tencent has received regulatory approval for “Tencent Brain Training,” its digital therapeutics software for mild cognitive impairment, marking its sixth medical device registration. This gamified software, prescribed by physicians, employs interactive tasks to enhance cognitive function, targeting the large population in China experiencing this condition. This non-pharmacological intervention aims to improve patient quality of life and potentially reshape treatment approaches for cognitive decline.